Pending FDA review and approval, research findings pave way for Akili’s EVO to become first brain training platform prescribed for ADHD

By SharpBrains | December 12, 2017

Akili Achieves Pri­ma­ry Effi­ca­cy End­point in ADHD Tri­al (MD mag­a­zine): “Boston-based Akili Inter­ac­tive has announced top-line results from the STARS-ADHD piv­otal study of its inves­ti­ga­tion­al dig­i­tal ther­a­peu­tic med­i­cine AKL-T01, in treat­ment of pedi­atric atten­­tion-deficit/hy­per­ac­­tiv­i­­ty dis­or­der (ADHD)…The dig­i­tal med­i­cine, AKL-T01, is a video game for patients to play on tablet devices. It uses the same storytelling…

Read More

The FDA clears two computerized cognitive tests to assist in medical evaluations following brain injury or concussion

By SharpBrains | August 26, 2016

FDA allows mar­ket­ing of first-of-kind com­put­er­ized cog­ni­tive tests to help assess cog­ni­tive skills after a head injury (FDA news release): “The U.S. Food and Drug Admin­is­tra­tion today per­mit­ted mar­ket­ing of two new devices to assess a patient’s cog­ni­tive func­tion imme­di­ate­ly after a sus­pect­ed brain injury or con­cus­sion. The Imme­di­ate Post-Con­­cus­­sion Assess­ment and Cog­ni­tive Test­ing (ImPACT)…

Read More

Update: Well-targeted brain training might significantly reduce dementia risk

By SharpBrains | July 28, 2016

Time for a new edi­tion of Sharp­Brains’ e‑newsletter. Hap­py read­ing! New brain research ACTIVE study: Well-tar­get­ed brain train­ing might sig­nif­i­cant­ly reduce demen­tia risk To improve brain health you need BOTH aer­o­bic and cog­ni­tive exer­cise A new era of brain car­tog­ra­phy, pow­ered by neu­roimag­ing and machine learn­ing New tools for brain health and per­for­mance Akili rais­es an…

Read More

Akili raises an additional $11.9M; brings Amgen, Merck, Pfizer and Shire to the digital medicine table

By SharpBrains | July 21, 2016

—– Akili Adds Amgen Ven­tures and M Ven­tures* to Series B Financ­ing, Increas­ing Round to $42.4 Mil­lion (press release): “Akili Inter­ac­tive Labs, Inc. (“Akili”), a dig­i­tal med­i­cine com­pa­ny devel­op­ing nov­el, non-phar­­ma­­co­log­i­­cal ther­a­peu­tics and diag­nos­tics for cog­ni­tive dis­or­ders, today announced an $11.9 mil­lion expan­sion of its recent Series B financing. 

Read More

Large multi-center study to test videogame-like digital therapy as (potentially) FDA-cleared ADHD treatment

By SharpBrains | May 10, 2016

Akili Labs recruits for ADHD tri­al with ambi­tions of FDA clear­ance for dig­i­tal med­i­cine (Med­C­i­ty News) “Akili Labs has kicked off open enroll­ment for a clin­i­cal tri­al of its Project EVO video game plat­form in a quest to secure for 510(k) clear­ance from the U.S. Food and Drug Admin­is­tra­tion for its lead indication

Read More